-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Veru Inc. (VERU) Investors to Approaching Deadline in Securities Class Action, Encourages Investors With Significant Losses to Contact Firm's Attorneys
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Veru Inc. (VERU) Investors to Approaching Deadline in Securities Class Action, Encourages Investors With Significant Losses to Contact Firm's Attorneys
San Francisco, California--(Newsfile Corp. - January 20, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.
Class Period: May 11, 2022 - Nov. 9, 2022
Lead Plaintiff Deadline: Feb. 6, 2023
Visit:
Contact An Attorney Now: VERU@hbsslaw.com
844-916-0895
Veru Inc. (NASDAQ: VERU) Securities Fraud Class Action:
The complaint alleges that throughout the Class Period, Defendants misrepresented and concealed material adverse facts about the data from the Phase 3 trial and the Company's interactions with the FDA concerning sabizabulin (VERU-111), its orally administered COVID 19 drug intended to treat hospitalized patients at high risk for acute respiratory distress syndrome.
Specifically, Veru misled investors into believing that the data from the Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application ("NDA") without any further studies. VERU's filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
Investors learned the truth on Nov. 9, 2022, when Veru announced that the FDA advisory committee ("AdCom") voted against approving sabizabulin under the agency's EUA pathway. Separately, AdCom's briefing document highlighted "several uncertainties in the data that may impact the clinical interpretation of the efficacy results."
This news sent the price of Veru shares crashing 53% lower in a single trading day.
"We're focused on investors' losses and proving Veru misled investors about the sufficiency of data it submitted in support of its sabizabulin EUA and about its communications with the FDA," said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in Veru and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.
Whistleblowers: Persons with non-public information regarding Veru should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email VERU@hbsslaw.com.
# # #
About Hagens Berman
Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 844-916-0895
To view the source version of this press release, please visit
San Francisco, California--(Newsfile Corp. - January 20, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.
加利福尼亚州旧金山--(Newsfile Corp. ——2023 年 1 月 20 日)——哈根斯·伯曼敦促 Veru Inc. (纳斯达克股票代码:VERU) 蒙受重大损失的投资者现在可以提交亏损。
Class Period: May 11, 2022 - Nov. 9, 2022
Lead Plaintiff Deadline: Feb. 6, 2023
Visit:
Contact An Attorney Now: VERU@hbsslaw.com
844-916-0895
上课时间: 2022 年 5 月 11 日-2022 年 11 月 9 日
首席原告截止日期: 2023年2月6日
访问:
立即联系律师: VERU@hbsslaw.com
844-916-0895
Veru Inc. (NASDAQ: VERU) Securities Fraud Class Action:
Veru Inc.(纳斯达克股票代码:VERU)证券欺诈集体诉讼:
The complaint alleges that throughout the Class Period, Defendants misrepresented and concealed material adverse facts about the data from the Phase 3 trial and the Company's interactions with the FDA concerning sabizabulin (VERU-111), its orally administered COVID 19 drug intended to treat hospitalized patients at high risk for acute respiratory distress syndrome.
该申诉称,在整个集体诉讼期间,被告歪曲和隐瞒了有关三期试验的数据以及该公司与美国食品药品管理局就sabizabulin(VERU-111)的互动的重大不利事实。sabizabulin()是其口服COVID 19药物,旨在治疗急性呼吸窘迫综合征高风险住院患者。
Specifically, Veru misled investors into believing that the data from the Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application ("NDA") without any further studies. VERU's filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
具体而言,Veru误导了投资者,使他们认为3期试验的数据足以支持紧急使用授权(“EUA”),甚至无需进一步研究即可提交新药申请(“NDA”)。因此,VERU的文件掩盖了该公司在获得EUA申请批准时面临的真正风险。
Investors learned the truth on Nov. 9, 2022, when Veru announced that the FDA advisory committee ("AdCom") voted against approving sabizabulin under the agency's EUA pathway. Separately, AdCom's briefing document highlighted "several uncertainties in the data that may impact the clinical interpretation of the efficacy results."
投资者在2022年11月9日得知了真相,当时Veru宣布美国食品药品管理局咨询委员会(“AdCom”)投票反对根据该机构的EUA途径批准sabizabulin。另外,AdCom的简报文件强调了 “数据中的一些不确定性,这些不确定性可能会影响疗效结果的临床解释。”
This news sent the price of Veru shares crashing 53% lower in a single trading day.
这一消息使Veru股票的价格在单个交易日内下跌了53%。
"We're focused on investors' losses and proving Veru misled investors about the sufficiency of data it submitted in support of its sabizabulin EUA and about its communications with the FDA," said Reed Kathrein, the Hagens Berman partner leading the investigation.
负责调查的哈根斯·伯曼合伙人里德·凯瑟琳说:“我们专注于投资者的损失,证明Veru在为支持sabizabulin EUA而提交的数据是否充足以及与美国食品药品管理局的沟通方面误导了投资者。”
If you invested in Veru and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.
如果您投资了Veru并蒙受了重大损失,或者掌握了可能有助于公司调查的知识,请单击此处与Hagens Berman讨论您的合法权利。
Whistleblowers: Persons with non-public information regarding Veru should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email VERU@hbsslaw.com.
举报人: 掌握有关Veru的非公开信息的人应考虑选择帮助调查或利用美国证券交易委员会举报人计划。根据新计划,提供原始信息的举报人可获得总额高达美国证券交易委员会成功追回资金的30%的奖励。欲了解更多信息,请致电 Reed Kathrein 844-916-0895 或者发送电子邮件至 VERU@hbsslaw.com。
# # #
# #
About Hagens Berman
Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
关于哈根斯·伯曼
哈根斯·伯曼是一家全国性律师事务所,在全国八个城市设有八个办事处,拥有八十多名律师。该公司在复杂的诉讼中代表投资者、举报人、工人和消费者。有关该公司及其成功案例的更多信息,请访问hbsslaw.com。要了解最新消息,请访问我们的新闻编辑室或在 Twitter 上关注我们,网址为 @classactionlaw。
Contact:
Reed Kathrein, 844-916-0895
联系人:
Reed Kathrein,844-916-0895
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧